VRDNViridian Therapeutics, Inc.
Price
-3.9%1YEnd-of-day closes, not the intraday tick.
The checks lean against it
Quality shaky, a flag to check, growing in the filings, the market against it.
We are a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases. We target therapeutic areas in which current treatments leave room for improvements in efficacy, safety, and/or dosing convenience. We believe there is significant potential in these areas, for better medicines that address unmet needs, improve outcomes, and expand treatment options for patients.
In the company’s own words · 10-K filed Feb 26, 2026 · SEC EDGAR
Charts
As reported to the SEC, without any scoring.
Viridian Therapeutics, Inc. (VRDN) reported revenue of $284K in Q2 2026 (quarter ended Jun 30, 2026), up 279% from the same quarter a year earlier. That came with net loss of $127M. For the full year FY2025, revenue was $71M (+23360% year on year) and net income −$343M. Its largest product in Q2 2026 was License at $233K, 82% of the disclosed total, well ahead of Collaboration at 18%. The next results filing is expected around Nov 4, 2026, the same week as a year ago.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 6, 2026Viridian Therapeutics Highlights Recent Business Progress and Reports Second.Earnings release · press release
- Jun 29, 2026On June 26, 2026, the Company announced that the FDA has approved Lumvoa ™ (veligrotug-vvze) for the treatment of TED regardless of activity or duration.Regulation FD disclosure · Form 8-K
- May 28, 2026On May 27, 2026, Viridian Therapeutics, Inc. (the “Company”) completed a voluntary prepayment of all outstanding principal, accrued and unpaid interest, fees, costs and expenses, equal to approximately $55.1 million in the aggregate (the “Payoff Amount”), under the Loan and Security Agreement, entered into and …Material agreement terminated · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
Business segments
Q2 2026 · $284.0KThe company’s own SEC segment disclosure.
- License$233.0K82%
- Collaboration$51.0K18%
Why these answers
Each answer with the checks it was read from. Open one for the numbers.
Conflicts between checks are named, never averaged, and thin data says so.